Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab.
暂无分享,去创建一个
Andreas Wolf | Dirk Nagorsen | Monika Brüggemann | P. Kufer | A. Wolf | P. Baeuerle | Y. Hijazi | G. Zugmaier | C. Brandl | R. Bargou | D. Hoelzer | Matthias Stelljes | M. Brüggemann | N. Gökbuget | Dieter Hoelzer | Patrick A Baeuerle | M. Stelljes | A. Viardot | Ralf C Bargou | D. Nagorsen | Max S Topp | Peter Kufer | Nicola Gökbuget | Mariele Goebeler | Matthias Klinger | Svenja Neumann | Andreas Viardot | Evelyn Degenhard | Gerhard Zugmaier | M. Topp | M. Klinger | Christian Brandl | Youssef Hijazi | S. Neumann | M. Goebeler | E. Degenhard | Evelyn Degenhard
[1] A. Bagg,et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. , 2011, The New England journal of medicine.
[2] C. Drake,et al. Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma , 2011, Clinical Cancer Research.
[3] H. Einsele,et al. Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody , 2008, Science.
[4] J. Schachter,et al. Focus on Adoptive T Cell Transfer Trials in Melanoma , 2010, Clinical & developmental immunology.
[5] R. Kimmig,et al. MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. , 2006, Molecular immunology.
[6] M. Kneba,et al. Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials. , 2007, Blood.
[7] P. Hoffmann,et al. Extremely potent, rapid and costimulation‐independent cytotoxic T‐cell response against lymphoma cells catalyzed by a single‐chain bispecific antibody , 2002, International journal of cancer.
[8] M. Smyth,et al. Immune surveillance of tumors. , 2007, The Journal of clinical investigation.
[9] D. Tough,et al. Qualitative differences between naïve and memory T cells , 2002, Immunology.
[10] R. Kischel,et al. Potent Control of Tumor Growth by CEA/CD3-bispecific Single-chain Antibody Constructs That Are Not Competitively Inhibited by Soluble CEA , 2009, Journal of immunotherapy.
[11] Steven A. Rosenberg,et al. Adoptive-cell-transfer therapy for the treatment of patients with cancer , 2003, Nature Reviews Cancer.
[12] P. Kufer,et al. Strictly Target Cell-dependent Activation of T Cells by Bispecific Single-chain Antibody Constructs of the BiTE Class , 2007 .
[13] Hermann Einsele,et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Xiaoling Hu,et al. Experimental metastasis and CTL adoptive transfer immunotherapy mouse model. , 2010, Journal of visualized experiments : JoVE.
[15] M. Kikuchi,et al. Clinical significance of minimal residual disease in adult acute lymphoblastic leukemia , 2010, International journal of hematology.
[16] H. Ueno,et al. Recent Developments in Cancer Vaccines , 2011, The Journal of Immunology.
[17] B. Dörken,et al. A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. , 2000, Blood.
[18] G. Willimsky,et al. The adaptive immune response to sporadic cancer , 2007, Immunological reviews.
[19] P. Baeuerle,et al. Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. , 2011, Experimental cell research.
[20] I. Davis,et al. Melanoma vaccines: developments over the past 10 years , 2011, Expert review of vaccines.
[21] A. Dalgleish,et al. Current status and future applications of cellular therapies for cancer. , 2011, Immunotherapy.
[22] D. Farber. Biochemical signaling pathways for memory T cell recall. , 2009, Seminars in immunology.
[23] A. Biondi,et al. Chimeric T-cell receptors: new challenges for targeted immunotherapy in hematologic malignancies. , 2007, Haematologica.
[24] P. Hoffmann,et al. Mode of cytotoxic action of T cell-engaging BiTE antibody MT110. , 2009, Immunobiology.
[25] J. Wolchok,et al. Targeting cytotoxic T-lymphocyte antigen 4 in immunotherapies for melanoma and other cancers. , 2010, Immunotherapy.
[26] R. Hansen,et al. Antibody pharmacokinetics and pharmacodynamics. , 2004, Journal of pharmaceutical sciences.
[27] P. Hoffmann,et al. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19‐/CD3‐bispecific single‐chain antibody construct , 2005, International journal of cancer.
[28] P. Kufer,et al. T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct , 2006, Cancer Immunology, Immunotherapy.
[29] M. Valsecchi,et al. Defining the correct role of minimal residual disease tests in the management of acute lymphoblastic leukaemia , 2011, British journal of haematology.
[30] G.,et al. Annexin V for Flow Cytometric Detection of Phosphatidylserine Expression on B Cells Undergoing Apoptosis , 2000 .
[31] M. Schmitt,et al. Clinical peptide vaccination trials for leukemia patients , 2011, Expert review of vaccines.